glp-1 for obesity Weighing the risk of treatment in older adults: Should we be concerned about sarcopenic obesity? What Are GLP-1 Agonists For

doi: 10.1001/jama.2017.2719 [DOI] [PMC free article] [PubMed] [Google Scholar] 41

When you know exactly what dose you are taking and exactly when you are taking it, correlating those numbers with your side effect and energy data becomes straightforward

Further research into the actions of glucagon has demonstrated a role in satiety, with acute administration in humans diminishing hunger and reducing food intake (43), whilst also stimulating energy expenditure and cardiac contractility (44, 45)

When in doubt, reach out to your pharmacist or healthcare provider

Rachel Pessah-Pollack explains the risks and benefits, who may be a candidate and more.

Furthermore, the anti-inflammatory properties of GLP-1 agonists and their ability to enhance gut barrier integrity align with leading theories about IBS pathophysiology, suggesting a mechanistic basis for clinical improvement